WEST LAFAYETTE, Ind., Oct. 22, 2008 (GLOBE NEWSWIRE) -- Kylin Therapeutics, Inc., a developer of next-generation RNAi therapeutics, announced the expansion of its research and development efforts. The project will advance promising new RNAi cancer therapies. This expanded effort will be conducted at Purdue University's Bindley Bioscience Center, and will focus on further validating targeted, systemically delivered cancer therapies utilizing Kylin's proprietary pRNAi platform. "Our in vivo efforts have shown pRNAi to be a very potent and versatile RNA inducing platform," said Eric Davis, the president and CEO of Kylin. "This expanded effort will enable us to test the flexibility of the pRNAi platform against various cancer targets."
